The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.
Japanese drugmaker Astellas expects to book an impairment charge of 70 billion yen ($453 million) in the fourth quarter of Japan’s 2023 fiscal year, which ended last month. 16 April 2024
US biotech Arrowhead Pharmaceuticals recently unveiled final data from its Phase II SHASTA-2 clinical trial for plozasiran, previously recognized as ARO-APOC3. 16 April 2024
USA-based rare seizure specialist Marinus Pharmaceuticals saw its shares crash, falling nearly 83% to $1.36, after it revealed that a trial failed to meet early stopping criteria. 16 April 2024
UK pharma major AstraZeneca has notched up another clinical success for its already blockbuster cancer drug Imfinzi (durvalumab) in biliary tract cancer. 16 April 2024
US immuno-oncology company Portage Biotech has only around a fifth of its stock market value since early Friday, when the firm reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its cash runway. 15 April 2024
The Phase I trial of NMRA-266 has been placed on clinical hold by the US Food and Drug Administration (FDA), said the drug’s developer, Massachusetts, USA-based based brain disease biotech Neumora Therapeutics. 15 April 2024
A US judge has dismissed a legal claim from pharma major Eli Lilly alleging that an online pharmacy illegally sold an unauthorized compounded version of the company's dual GIP and GLP-1 receptor agonist tirzepatide. 15 April 2024
Japanese drugmaker Nxera Pharma has entered into an exclusive supply and distribution agreement with Handok to commercialize Pivlaz (clazosentan sodium) 150mg in South Korea. 15 April 2024
Roche’s CD20xCD3 T-cell engaging bispecific antibody Columvi (glofitamab) has met the primary endpoint of overall survival in relapsed or refractory diffuse large B-cell lymphoma in the Phase III STARGLO study. 15 April 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024